These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 35833116)
1. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Huang Z; Pang X; Zhong T; Qu T; Chen N; Ma S; He X; Xia D; Wang M; Xia M; Li B Front Immunol; 2022; 13():924542. PubMed ID: 35833116 [TBL] [Abstract][Full Text] [Related]
2. Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204). Zheng Y; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Xu N Cancer; 2024 Jun; 130(12):2180-2190. PubMed ID: 38412283 [TBL] [Abstract][Full Text] [Related]
3. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ MAbs; 2015; 7(3):494-504. PubMed ID: 25933349 [TBL] [Abstract][Full Text] [Related]
4. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). Song Y; Zhou K; Jin C; Qian Z; Hou M; Fan L; Li F; Ding K; Zhou H; Li X; Chen B; Sun X; Song X; Jiang M; Zhang Q; Liu L; Yu G; Hu Y; Zhao Z; Liu L; Xue H; Luo J; He B; Jin X; Zhao M; Li B; Xia Y; Zhu J Front Oncol; 2022; 12():925236. PubMed ID: 35875118 [TBL] [Abstract][Full Text] [Related]
6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058 [TBL] [Abstract][Full Text] [Related]
7. Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies. Zhang W; Chen X; Chen X; Li J; Wang H; Yan X; Zha H; Ma X; Zhao C; Su M; Hong L; Li P; Ling Y; Zhao W; Xia Y; Li B; Zheng T; Gu J J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925680 [TBL] [Abstract][Full Text] [Related]
8. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G Front Immunol; 2019; 10():562. PubMed ID: 30984171 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P MAbs; 2015; 7(4):743-51. PubMed ID: 25970007 [TBL] [Abstract][Full Text] [Related]
10. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029 [TBL] [Abstract][Full Text] [Related]
11. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Zheng Y; Mislang ARA; Coward J; Cosman R; Cooper A; Underhill C; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Jin X; Li B; Wang ZM; Kwek KY; Xia D; Xia Y; Xu N Cancer Immunol Immunother; 2022 Oct; 71(10):2371-2379. PubMed ID: 35165764 [TBL] [Abstract][Full Text] [Related]
13. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. Chung AW; Crispin M; Pritchard L; Robinson H; Gorny MK; Yu X; Bailey-Kellogg C; Ackerman ME; Scanlan C; Zolla-Pazner S; Alter G AIDS; 2014 Nov; 28(17):2523-30. PubMed ID: 25160934 [TBL] [Abstract][Full Text] [Related]
14. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Han C; Ye S; Hu C; Shen L; Qin Q; Bai Y; Yang S; Bai C; Zang A; Jiao S; Bai L Front Oncol; 2021; 11():684867. PubMed ID: 34327136 [TBL] [Abstract][Full Text] [Related]
15. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484 [TBL] [Abstract][Full Text] [Related]
16. Role of Fcγ receptors in HER2-targeted breast cancer therapy. Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090 [TBL] [Abstract][Full Text] [Related]
17. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report. Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899 [TBL] [Abstract][Full Text] [Related]
18. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936 [TBL] [Abstract][Full Text] [Related]
19. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066 [TBL] [Abstract][Full Text] [Related]